Global Human Microbiome Market, By Product Type [Food (Probiotics, Prebiotics, Medical Food Supplements, Others (Symbiotic, Antibiotics, etc.)), Microbome Drugs, Fecal Microbiota Transplant], By Application [Therapeutics, Diagnostics, Nutrition and Deities, Others (Cosmetics, Animal health etc.)], By Disease Indication (Auto Immune Disorder, Clostridium Difficile Infection, Metabolic Disorder, Inflammatory Bowel disorder, Infectious Diseases, and Others (Cancer, Rare Diseases), By Distribution Channel (Hospital, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 617.9 Million in 2023, and is expected to exhibit a CAGR of 24.6% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Key market players are focusing on adoption of growth strategies such as commercialization of microbiome-based diagnostics and therapeutics, new techniques to identify interactions between microbiota and disease, key technologies for the discovery of microbiome-based medicines, latest research and developments in skin, gut, and oral microbiome which will drive the global human microbiome market growth. For instance, In July 2022, Uniliver, a multinational fast-moving consumer goods (FMCG) company, partnered with IBM, a technology innovator, leading advances in AI, automation and hybrid cloud solutions, and Eagle Genomics, a software solutions company, to enable the management, orchestration and exploitation of life sciences, for unraveling the ways of increasing natural ceramide production in the skin by incorporating ceramide precursors into its skincare products.
Global Human Microbiome Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the research and development due to disordered clinical trials worldwide delays and lower participation in trials.
However, COVID-19 had positive impact on the global human microbiome market. For instance, in March 2021, Frontiers magazine published an article under the section Infectious Diseases on ongoing research on direct bidirectional relationships between the COVID-19 virus and the lung and gut microbiomes. Changing health and cleanliness, as well as mood and food, could all result in long-term alterations to the gut microbiota on an individual and national basis.
Global Human Microbiome Market: Key Developments
- In September 2020, Finch Therapeutics, a clinical-stage microbiome drug development company, granted US$ 90 Million financing in order to advance pipeline of investigational oral microbiome drugs, focusing on phase iii clinical trial CP101 an oral drug for treatment for CDI or CDI difficile, and to sudy CP101 for the many other conditions linked to microbiome disruption like chronic hepatitis B.
- In November 2022, Ferring B.V., a global pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved REBYOTA (fecal microbiota, live-jslm), a novel drug for microbiota-based live biotherapeutic drug which is indicated for the prevention of recurrence of Clostridioides difficile (C. difficile) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
- On April 26, 2023, Seres Therapeutics, a commercial stage microbiome threpeutics manufacturing company, and Nestlé Health Science, a global leading company in nutrition science, announced that U.S. food and Drug Administration (FDA) granted approval for VOWST, a the first orally administered microbiota-based therapeutic for the prevention of recurring C. difficile infection. The Clostridium Difficile Infection segment of Disease indication segment is expected to be the fastest-growing segment during the forecast period.
- On July 20, 2023, MaaT Pharma, a clinical stage biotechnology company and a leading developer of microbiome ecosystem therapies, joins the Microbiome Therapeutics Innovation Group (MTIG), a alliance of companies leading to the research and development of FDA-approved microbiome-based products and microbiome therapeutic drugs to address different medical conditions which are not addressed previously and to improve clinical outcomes, and reduce cost for health care.
Browse 36 Market Data Tables and 26 Figures spread through 180 Pages and in-depth TOC on “Global Human Microbiome Market, By Product Type [Food (Probiotics, Prebiotics, Medical Food Supplements, Others (Cosmetics, Animal health etc.))], , Microbome Drugs, Fecal Microbiota Transplant], By Application [Therapeutics, Diagnostics, Nutrition and Deities, Others (Cosmetics, Animal health etc.)] By Disease Indication (Auto Immune Disorder, Clostridium Difficile Infection, Metabolic Disorder, Inflammatory Bowel disorder, Infectious Diseases, Others (Cancer, Rare Diseases), By Distribution Channel (Hospital, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182
Key Takeaways of the Global Human Microbiome Market:
- Global human microbiomemarket is expected to exhibit a CAGR of 24.6% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global human microbiome market.
- Among Therapeutic segment Application is expected to hold a dominant position in the global Human Microbiome market during the forecast period due to ongoing research and development in the microbiome based products and drugs and rising funding from bigger MNCs and pharmaceutical companies supporting researches of smaller firms. For instance, in December 2022, Biomica, a subsidiary of Evogene Ltd., a clinical-stage biopharmaceutical company that develops therapies for immuno-oncology, antibiotic resistant bacteria, and microbiome-related gastrointestinal (GI) disorders, recived a funding of US$ 20 million by Shanghai Healthcare Capital (SHC).
- Among region, North America is expected to be the dominant region in the global human microbiome market, owing to the increasing incidences of various gut disorders and increased awareness about prebiotics and probiotics for their role in preventive health measures and in balancing gut Microbiome. Key players focusing on organic strategies such as research and development and for innovation in drug development for various unexplored area of diseases. For instance, in March 2022, MaaT Pharma, a clinical-stage microbiome therapeutics company, is developing MaaT013 Drug which is under Phase III clinical trial for indication in treatment of acute acute graft versus host disease in intestine (GVHD).
- Major players operating in the global human microbiome market are Seres Therapeutics, Biomesense, Microbiotica, Infant Bacterial Therapeutics AB, Vedanta Biosciences, Inc., Second genome therapeutics, 4D Pharma Ferring Inc, Enterome, BiomX, MaaT Pharma, Azitra, Illumina, Inc, Locus Biosciences, Inc, Finch Therapeutics Group, Inc, Rebiotix Inc, Servatus Ltd, Microbiome Research Pvt. Ltd, AOBiome, Axial Therapeutics, Inc, Biomica.
